What happened with PLRX today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Pliant Therapeutics is a clinical-stage drug developer whose lead candidate, PLN-101095, is an oral medicine being tested for solid tumors resistant to immune checkpoint inhibitors. The company wholly owns the candidate, which targets two integrins and is in a Phase 1 trial. It has no approved products and currently generates no revenue; it is developing potential treatments rather than selling medicines to patients.
Pliant has financed operations mainly by selling shares and through its former collaboration with Novartis. It needs additional capital to complete clinical development, and product sales would require further trials and regulatory approval. It also outsources all clinical manufacturing, relying on sole suppliers without long-term supply agreements, so continued development depends on outside funding and access to drug supplies.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
After discontinuing bexotegrast, Pliant depends on PLN-101095 clinical results and funding, while privately held CatalyM is another TGF-β-pathway competitor to watch beyond this list.
Bicara Therapeutics Inc. competes with Pliant’s integrin-based treatment approach for checkpoint-resistant solid tumors through ficerafusp alfa, designed to suppress TGF-β within tumors. Watch results from Bicara’s trial combining ficerafusp alfa with pembrolizumab for evidence of how this competing approach performs.
Scholar Rock Holding Corporation’s SRK-181 competes directly with Pliant’s PLN-101095 in solid tumors resistant to checkpoint treatment, with both approaches targeting the TGF-β pathway. Although Scholar Rock mainly develops drugs for rare neuromuscular diseases, its search for a partner for SRK-181 is the development to watch for Pliant.
Fed Interest Rate Decision
Pliant’s policy-rate backdrop affects the interest income it earns as its money-market funds and debt securities mature or are reinvested, alongside the cash it uses to fund research and development.
Expected4.0%Last release4.0%
If it comes in above expectations
If rates rise more than expected, Pliant may earn more interest as its investments mature and are reinvested, adding to income that helps fund its research and development.
If it comes in below expectations
If rates fall more than expected, Pliant may earn less interest as its investments mature and are reinvested, leaving less income to help fund its research and development.
Pliant Therapeutics, Inc. earningsThis company
Pliant Therapeutics has no product sales and spends cash to advance PLN-101095, so this report will show whether its research costs and cash use are matched by progress in the program.
Read research and development spending alongside the cash balance, and check for progress in the PLN-101095 trial. Lower spending and slower cash use with the program moving forward would show Pliant is preserving runway without abandoning development; rising spending or faster cash use without corresponding progress would mean its limited funds are being depleted sooner, making financing more pressing.
Bicara Therapeutics Inc. earningsBCAX
Bicara Therapeutics’ report will show how its ficerafusp alfa and pembrolizumab trial is progressing, giving a read on the competing tumor-environment approach alongside Pliant Therapeutics’ PLN-101095.
Look for trial progress and signs of activity in Bicara Therapeutics’ combination study. Clear activity would suggest its approach of suppressing TGF-β within tumors could draw clinical attention and compete with Pliant Therapeutics’ integrin-targeting PLN-101095 for development resources and future partnerships; limited or unclear results would weaken the case for this competing approach, but would not prove PLN-101095 works.
Scholar Rock Holding Corporation earningsSRRK
Scholar Rock’s report will show whether SRK-181 has found a partner, indicating whether this competing tumor program alongside Pliant Therapeutics’ PLN-101095 can attract outside support.
Watch for any disclosed partnership progress for SRK-181. A partner would show that an outside company is willing to fund this competing TGF-β-pathway program for checkpoint-resistant tumors, potentially adding pressure on Pliant Therapeutics to secure development funding or partners; no progress would leave SRK-181’s path less certain, not make PLN-101095 the winner.
